inVentiv Health Announces New Sales Team Agreement With Novartis Pharmaceuticals Corporation

SOMERSET, N.J., Aug. 8 /PRNewswire-FirstCall/ -- inVentiv Health, Inc. today announced that it has signed a new sales team contract with Novartis Pharmaceuticals Corporation.

This multi-year agreement is expected to commence in the fourth quarter of 2006. Further details of the contract were not disclosed.

Mr. Terry Herring, President and Chief Executive Officer of inVentiv Commercial stated, "We are extremely honored to have been awarded this significant new contract with Novartis. This is a major new sales team relationship for us, and we look forward to building a longstanding and mutually-beneficial relationship with Novartis."

About inVentiv Health

inVentiv Health, Inc. is the leading provider of commercialization and complementary services to the global pharmaceutical, life sciences and biotechnology industries. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its three core business segments: inVentiv Clinical, inVentiv Communications and inVentiv Commercial. inVentiv Health currently works with over 200 unique pharmaceutical, biotech and life sciences clients, including all top 20 global pharmaceutical companies. For more information, visit http://www.inventivhealth.com.

Forward-Looking Information

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause Ventiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health, Inc. with the Securities and Exchange Commission for further discussion of these and other factors.

CONTACT: Investors/Corporate: John Emery, CFO, +1-732-537-4804,investor@inventivhealth.com, Media: Felicia Vonella, +1-212-308-7155,fvonella@inventivhealth.com, both of inVentiv Health, Inc.

Web site: http://www.inventivhealth.com/